当前位置: 首页 > 详情页

Seletracetam enhances short term depression in vitro

| 导出 | |

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [a]Department of Neurology, University of Minnesota Medical School, Minneapolis, MN, USA [b]Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN, USA [c]Mercy Clinic Child Neurology, St. Louis, MO, USA [d]Electrophysiology Laboratory, Xuanwu Hospital, Capital Medical University, Beijing, China
出处:
ISSN:

关键词: Antiepileptic drugs Anticonvulsants Epilepsy Seletracetam Levetiracetam SV2A Synaptic vesicles

摘要:
Seletracetam (SEL), an analog of the antiepileptic drug levetiracetam (LEV), decreases seizure activity in a number of epilepsy models and binds to the synaptic vesicle protein SV2A with a higher affinity than LEV. Experiments were performed to determine if SEL, like LEV, reduces the later EPSPs in long trains of stimuli in a manner dependent upon access to the interior of synaptic vesicles and SV2A binding. When hippocampal slices were incubated in 3-30 mu M SEL for 3 h, but not 30 min, the relative amplitude of the CA1 field excitatory synaptic potentials decreased over the course of a train of high frequency stimuli more than for control slices. This short term depression was frequency and dose dependent and largely disappeared when the spontaneous activity during the loading period was removed by cutting the Schaffer collaterals. The SEL effect was also observed in slices loaded during prolonged stimulation at 1 Hz, but not 10 Hz. Hippocampal slices loaded with both SEL and FM1-43 to visualize synaptic boutons released the FM1-43 in response to prolonged stimulation much more slowly than control slices during prolonged stimulation. Like LEV, SEL produced a frequency-dependent decrement of synaptic transmission that was dependent upon the drug entering recycling synaptic vesicles and compatible with SV2A binding. Previous observations of SV2A binding affinity correlated with the current effect of SEL and the previously reported effect of LEV on synaptic transmission validate SV2A as an extremely attractive target for future antiepileptic drug development. (C) 2015 Elsevier B.V. All rights reserved.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2014]版:
大类 | 3 区 医学
小类 | 4 区 临床神经病学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 临床神经病学
JCR分区:
出版当年[2013]版:
Q2 CLINICAL NEUROLOGY
最新[2023]版:
Q3 CLINICAL NEUROLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版] 出版后一年[2014版]

第一作者:
第一作者机构: [a]Department of Neurology, University of Minnesota Medical School, Minneapolis, MN, USA [d]Electrophysiology Laboratory, Xuanwu Hospital, Capital Medical University, Beijing, China
通讯作者:
通讯机构: [*1]6-145 Jackson Hall, 321 Church St SE, Minneapolis,MN 55455, USA.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院